Welcome to our dedicated page for ENDRA Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on ENDRA Life Sciences stock.
ENDRA Life Sciences Inc. (symbol: NDRA), is revolutionizing the field of ultrasound with its groundbreaking photo-acoustic solutions. The company’s innovations enable medical researchers to screen and modify disease models with unmatched quality and speed. ENDRA Life Sciences has established a global installed base of top-tier institutions utilizing their Nexus-128 system, the only comprehensive 3D imaging solution designed for imaging anatomy, physiology, and labeled molecular targets.
The Nexus 128 is a sophisticated preclinical photoacoustic computed tomography (CT) scanner tailored for small animal imaging. It facilitates quick, non-invasive quantification of physiological parameters, such as tumor vasculature, without the need for ionizing radiation. The fully 3D imaging technology of the Nexus 128 enhances sensitivity compared to traditional slice-based scanners, and its dynamic (4D) photoacoustic CT scans support advanced applications like quantification of probe uptake. Currently, leading imaging laboratories worldwide leverage the Nexus 128 for various research purposes.
Additionally, ENDRA Life Sciences is developing Thermo Acoustic Enhanced UltraSound (TAEUS) technology, which aims to visualize tissue with MRI-like clarity but at a fraction of the cost and at the point of patient care. The TAEUS technology is designed to integrate with approximately 400,000 cart-based ultrasound systems in use globally. Initially, TAEUS focuses on measuring liver fat to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions affecting over a billion people worldwide, for which there are currently no effective diagnostic tools. Beyond liver applications, TAEUS is also being explored for several other clinical uses, such as visualizing tissue temperature during energy-based surgical procedures.
ENDRA Life Sciences continues to push the boundaries of medical imaging technology, collaborating with various partners to further enhance their solutions. Stay updated with the latest achievements, projects, and news from ENDRA Life Sciences to understand their impact and progression in the medical technology landscape.
ENDRA Life Sciences (NASDAQ:NDRA) reported its financial results for Q4 and FY 2020, with a net loss of $2.3 million ($0.10/share) in Q4, down from $4.8 million in 2019. Total operating expenses decreased to $2.3 million from $3.1 million in Q4 2019. For the full year, net loss was $11.7 million ($0.63/share), improved from $13.3 million in 2019. The company secured partnerships and clinical studies in Europe, strengthened its intellectual property, and raised $18.5 million through stock sales. A call to discuss results was scheduled for 4:30 PM ET today.
ENDRA Life Sciences (NASDAQ:NDRA) has partnered with Hepion Pharmaceuticals (NASDAQ:HEPA) to integrate its innovative TAEUS technology into Hepion's Phase 2b trial for CRV431, targeting non-alcoholic steatohepatitis (NASH). This collaboration aims to enhance patient screening and biomarker measurement, providing a cost-effective and non-invasive method for liver fat assessment. Positive topline data has been reported from Hepion's Phase 2a AMBITION trial, with patient enrollment for the Phase 2b study set to commence in late 2021, signaling advancements in liver disease treatments.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) will report its fourth quarter 2020 financial results on March 25, 2021, after market close. A conference call and webcast are scheduled for 4:30 p.m. Eastern time, allowing management to discuss the financial results and recent corporate updates. The company is known for its Thermo Acoustic Enhanced UltraSound (TAEUS) technology, aimed at diagnosing chronic liver conditions affecting over 1 billion people globally. The details for participation and access to a replay are included in the press release.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) will participate in two upcoming virtual investment conferences. The H.C. Wainwright Global Life Sciences Virtual Conference is scheduled for March 9-10, 2021, where management will give a presentation and hold one-on-one meetings. A recorded presentation will be available on demand from March 9, 2021. The 33rd Annual ROTH Conference will take place from March 15-19, 2021, with similar opportunities. ENDRA develops the Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, aiming to improve liver health diagnostics.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) has announced a new clinical study partnership with Inselspital University Hospital in Bern, Switzerland, focusing on the TAEUS ultrasound device for assessing Non-Alcoholic Fatty Liver Disease (NAFLD). This collaboration marks ENDRA's third clinical research partnership in Europe and aims to validate TAEUS as a non-invasive alternative to more invasive diagnostic techniques, involving 75 patients. The study data will enhance clinical evidence for TAEUS as commercialization efforts advance in Europe, alongside a recent collaboration renewal with GE Healthcare.
ENDRA Life Sciences (NASDAQ:NDRA) has been awarded U.S. Patent 10898166, enhancing its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology. This patent focuses on systems for imaging biological tissue structures, complementing prior patents and expanding ENDRA's intellectual property (IP) portfolio to 80 assets. The company aims to apply TAEUS® in critical areas like Non-Alcoholic Fatty Liver Disease (NAFLD). With ongoing clinical partnerships and a commercial launch planned, ENDRA is positioning TAEUS® as a cost-effective alternative to MRI for liver condition diagnostics.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) has been granted its 13th U.S. patent, number 10888898, for its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which offers enhanced imaging capabilities for diagnosing Non-Alcoholic Fatty Liver Disease (NAFLD). This patent solidifies intellectual property protection in a market where NAFLD affects 30% of the U.S. population. ENDRA's commercial launch plans include establishing international research partnerships, with recent installations in major hospitals. The company continues to expand its patent portfolio, now totaling 78 assets.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) will present at the H.C. Wainwright Virtual BioConnect 2021 Conference from January 11-14, 2021. Chairman and CEO Francois Michelon will showcase the company's innovative Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which visualizes tissue at a fraction of the cost of MRI, aimed initially at assessing Non-Alcoholic Fatty Liver Disease (NAFLD). The presentation will be available on the company's website starting January 11 at 6:00 a.m. Eastern time and archived for 90 days.
ENDRA Life Sciences (NASDAQ:NDRA) has been granted Chinese Patent ZL 2018 8 00500526 for its Thermo Acoustic Enhanced UltraSound (TAEUS) technology. This patent, the eighth for ENDRA in China, enhances its intellectual property portfolio, now totaling 78 assets. TAEUS provides a non-invasive method to assess liver fat, crucial for the estimated 30% of China's population suffering from Non-Alcoholic Fatty Liver Disease (NAFLD). The technology offers a cost-effective alternative to MRIs and biopsies, utilizing existing ultrasound systems for patient care.
ENDRA Life Sciences (NASDAQ: NDRA) has renewed its collaboration agreement with GE Healthcare, extending the partnership until December 16, 2023. This agreement will support the commercialization of ENDRA's TAEUS technology for imaging Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). Recent advancements include deployment of TAEUS systems at Rocky Vista University and UPMC, a clinical evaluation agreement in France, and an exclusive distribution deal in Vietnam for over 40 systems. ENDRA aims to enhance ultrasound capabilities and address critical clinical needs in liver assessments.
FAQ
What is the current stock price of ENDRA Life Sciences (NDRA)?
What is the market cap of ENDRA Life Sciences (NDRA)?
What does ENDRA Life Sciences Inc. specialize in?
What is the Nexus-128 system?
What are the applications of the TAEUS technology?
Who uses the Nexus-128 system?
How does the Nexus-128 system benefit medical research?
What are NAFLD and NASH?
How is TAEUS technology integrated into existing ultrasound systems?
What makes ENDRA's imaging technology unique?
Are there other clinical applications for TAEUS technology?
Where can I find the latest news and updates about ENDRA Life Sciences?
